New hope for blood cancer patients in japan?

NCT ID NCT06035497

Ongoing Disease control Sponsor: Bristol-Myers Squibb Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing a new drug called Golcadomide (BMS-986369) in about 85 people in Japan whose T-cell lymphoma has come back or not responded to treatment. The goal is to check the drug's safety and how well it works against the cancer. Participants will receive the drug and be monitored for side effects and tumor response.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

adult T-cell leukemia/lymphoma ALK-negative anaplastic large cell lymphoma ALK-positive anaplastic large cell lymphoma anaplastic large cell lymphoma angioimmunoblastic T-cell lymphoma breast implant-associated anaplastic large cell lymphoma extranodal nasal NK/T cell lymphoma Leukemia-Lymphoma, Adult T-Cell lymphoma Lymphoma, Extranodal NK-T-Cell mature T-cell and NK-cell non-Hodgkin lymphoma mycosis fungoides Nodal T-follicular helper cell lymphoma, follicular type peripheral T-cell lymphoma, not otherwise specified Precursor T-Cell Lymphoblastic Leukemia-Lymphoma Recurrence T-cell non-Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RELAPSED OR REFRACTORY T-CELL LYMPHOMAS

Contacts and locations

Locations

Local Institution - 0001

Sendai, Miyagi, 980-8574, Japan
Local Institution - 0002

Kashiwa, Chiba, 277-8577, Japan
Local Institution - 0003

Chuo-ku, Tokyo, 104-0045, Japan
Local Institution - 0004

Isehara, Kanagawa, 259-1193, Japan
Local Institution - 0005

Ōsaka-sayama, Osaka, 589-8511, Japan
Local Institution - 0006

Kumamoto, 860-8556, Japan
Local Institution - 0007

Okayama, 700-8558, Japan
Local Institution - 0008

Kagoshima, 890-8520, Japan
Local Institution - 0009

Hidaka, Saitama, 350-1298, Japan
Local Institution - 0010

Osaka, 541-8567, Japan
Local Institution - 0011

Nagoya, Aichi-ken, 467-8602, Japan
Local Institution - 0012

Fukuoka, 812-8582, Japan
Local Institution - 0013

Yokosuka, Kanagawa, 238-8558, Japan
Local Institution - 0015

Kagoshima, 890-0064, Japan
Local Institution - 0016

Iizuka, Fukuoka, 820-8505, Japan
Local Institution - 0017

Kamogawa, Chiba, 296-0041, Japan
Local Institution - 0018

Fukuoka, 810-8563, Japan
Local Institution - 0019

Ōmura, Nagasaki, 8568562, Japan
Local Institution - 0020

Ōita, 870-8511, Japan
Local Institution - 0022

Mitaka, 181-8611, Japan
Local Institution - 0023

Fukuoka, 814-0180, Japan
Local Institution - 0024

Toyohashi, Aichi-ken, 441-8570, Japan
Local Institution - 0025

Hiroshima, 7348551, Japan
Local Institution - 0026

Minato-ku, Tokyo, 105-8471, Japan
Local Institution - 0027

Kyoto, 602-8566, Japan
Local Institution - 0028

Sasebo, Nagasaki, 857-8511, Japan
Local Institution - 0029

Itabashiku, Tokyo, 173-8610, Japan
Local Institution - 0030

Nagasaki, 852-8104, Japan
Local Institution - 0031

Anjo-shi, Aichi-ken, 446-8602, Japan
Local Institution - 0032

Amagasaki, Hyōgo, 660-8550, Japan
Local Institution - 0033

Kobe, Hyōgo, 650-0047, Japan
Local Institution - 0034

Osaka, 545-8586, Japan
Local Institution - 0035

Kumamoto, 860-0008, Japan
Local Institution - 0036

Sapporo, Hokkaido, 0608648, Japan
Local Institution - 0037

Narita, Chiba, 286-8520, Japan
Local Institution - 0038

Miyazaki, 889-1692, Japan
Local Institution - 0039

Hiroshima, 730-0052, Japan
Local Institution - 0040

Koto, Tokyo, 135-8550, Japan
Local Institution - 0041

Kitakyushu-shi, Fukuoka, 806-8501, Japan
Local Institution - 0042

Okinawa, 904-2142, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.